Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce important new data from our ongoing ACCENT clinical trial in pancreatic cancer. The trial is investigating the Company’s best-in-class FAK inhibitor narmafotinib in combination with standard-of-care chemotherapies gemcitabine and Abraxane. Fifteen (15) confirmed partial responses (PRs) have…
Greenvale Energy (GRV:AU) has announced Multiple Uranium Anomalies Identified at Key NT Projects Download the PDF here. This post…
Errawarra Resources Ltd (ASX: ERW) is pleased to advise that recent surface sampling at its Elizabeth Hill Project has…
Saga Metals Corp. (‘SAGA’ or the ‘Company’) (TSXV: SAGA) (OTCQB: SAGMF) (FSE: 20H) a North American exploration company specializing…
Tolu Minerals Limited (“Tolu”) is pleased to announce the granting of its Ipi River tenement EL 2780 (Figure 1)…
Eric Nuttall, partner and senior portfolio manager at Ninepoint Partners, shares his outlook for oil and natural gas, honing…
American Salars Lithium Inc. (‘AMERICAN SALARS’ OR THE ‘COMPANY’) (CSE: USLI, OTC: ASALF, FWB: Z3P, WKN: A3E2NY ) announces…
Just in time for Canada Crypto Week, Robinhood Markets (NASDAQ:HOOD) has announced a definitive agreement to acquire Canadian digital…
Rare earths are important for many of today’s technologies and tomorrow’s carbon-free economy. Investors may not be very familiar…